Insight Molecular Diagnostics opened lower at $2.35, compared with its previous close of $2.39. In the last trading session, the stock traded between $2.19 and $2.39. It showed a downward intraday trend.
An investment of $100 made 2 years ago in Insight Molecular Diagnostics is now worth
$ 72.63
Resulting in a loss of
$ 27.37 (27.37%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.10 (-3.97%)
Day High
$2.39
Day Low
$2.19
Day Open
$2.35
Prev Close
$2.39
Volume
1,00,362
1W Return
-13.43%
1M Return
-27.60%
3M Return
-48.30%
6M Return
-53.26%
1Y Return
-69.50%
Market Cap ($ Mn)
75
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-
ROCE
-145.42%
EPS (TTM)
$-0.35
1 Week
-13.43%
1 Month
-27.60%
3 Months
-48.30%
6 Months
-53.26%
9 Months
-59.95%
iMDx replaces Chronix royalty with sale payment
iMDx replaces ongoing 10% CNI Monitor royalty with 10% sale proceeds payment. Ongoing royalty terminates upon sale of substantially all CNI Monitor rights. Amendment No. 2 signed on September 15, 2026, with equity holder representative. Previous 2023 amendment had eliminated milestone payments and higher royalty rates.
1mo agoInsight Molecular Q2FY26 Results: Cash burn rises to $10 million
Cash burn reached $10 million in Q2 2026, above the prior guidance of $6 million. Adjusted EBITDA loss narrowed to $7.8 million as core spending fell from Q4 2025 peak. Company targets FDA marketing authorization for Graftasure DX later this year. Medicare LCD expansion boosts testing frequency, supporting a $2 billion TAM baseline.
2mo agoNeedham reiterates Buy on Insight Molecular, keeps $9 target
Needham analyst Mike Matson reiterated a Buy rating on Insight Molecular (NASDAQ: IMDX) with an unchanged price target of $9. The action indicates sustained confidence in the company’s fundamentals without any adjustment to the previous valuation estimate.
2mo agoInsight Molecular Diagnostics hosts virtual KOL event on GraftAssure platform
Insight Molecular Diagnostics Inc. announced a virtual key opinion leader event on August 17, 2026, featuring Max Jacob Liebo, MD, Nick Ioannou, MD, MHA, and Josh Riggs. The discussion centers on the GraftAssure platform, which uses digital PCR technology for donor-derived cell-free DNA results in transplant monitoring.
3mo agoInsight Molecular Q2 EPS beats as FDA review advances
Insight Molecular Diagnostics reported Q2 2026 adjusted EPS of $(0.23), beating estimates, while revenue missed by 45%. The FDA advanced the review of GraftAssureDx, and Medicare expanded dd-cfDNA testing reimbursement.
3mo agoMedicare policy boosts iMDx transplant testing frequency
Insight Molecular Diagnostics Inc. secured a favorable Medicare policy on July 16, 2026, expanding coverage for dd-cfDNA testing. The policy increases surveillance testing frequency for kidney and heart transplants, removing the testing ceiling for years four and beyond. This supports iMDx's $2 billion market opportunity and its strategy to sell GraftAssureDx kits for in-house testing.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $717.71 | -0.07% | $2,65,923.04M | 33.49 | |
| $235.31 | -0.34% | $1,65,547.88M | 38.52 | |
| $702.59 | +0.85% | $55,354.26M | 39.00 | |
| $176.95 | -0.52% | $49,887.34M | 30.34 | |
| $319.82 | +2.51% | $46,375.50M | - | |
| $470.90 | -0.97% | $46,282.88M | 104.98 | |
| $274.53 | -0.23% | $45,242.54M | 32.52 | |
| $1,749.01 | -0.14% | $34,787.81M | 31.52 | |
| $212.93 | -0.92% | $32,195.02M | 40.22 | |
| $372.23 | +0.36% | $30,225.08M | 27.72 | |
| $258.69 | +0.10% | $28,460.82M | 25.77 | |
| $154.78 | -0.37% | $20,939.57M | - |
An investment of $100 made 2 years ago in Insight Molecular Diagnostics is now worth
$ 72.63
Resulting in a loss of
$ 27.37 (27.37%)
Note: Past profits do not guarantee future returns.
